1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson, CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA1994;272:205–11.
2.
2. Foreyt JP, Goodrick, GK. The ultimate triumph of obesity. Lancet1995;346:134–5.
3.
3. Wolf AM, Colditz, GA. The cost of obesity: the U.S. perspective. Pharmaco Economics1994;5(Suppl 1):34–7.
4.
4. Wolf AM, Colditz, GA. Social and economic effects of body weight in the United States. Am J Clin Nutr1996;63(Suppl):466S–9S.
5.
5. Bray GA, Ryan, DH. Drugs used in the treatment of obesity. Diabetes Rev1997;5:83–103.
6.
6. Bray, GA. Drug treatment of obesity: don't throw the baby out with the bath water. Am J Clin Nutr1998;67:1–2.
7.
7. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther1992;51:586.
8.
8. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study IV (weeks 156 to 190): the second double-blind phase. Clin Pharmacol Ther1992;51:608.
9.
9. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalences and trends, 1960–1994. Int J Obes Relat Metab Disorders1998;22:39–47.
10.
10. Hirsch, J. The treatment of obesity with drugs. Am J Clin Nutr1998;67:2–4.
11.
11. Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med1996;335:609–16.
12.
12. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med1997;337:581–8.
13.
13. Milloy SJ, Miller, HI. A diet prescription for trial lawyers. Investor's Business Daily1997 Nov 24.
14.
14. Lerman, RH. Obesity. An escalating problem. PART II What are the options in pharmacotherapy?. Contemp Intern Med1997;9:9–19.
15.
15. Wyeth-Ayerst Laboratories Press Release. Wyeth-Ayerst provides background information on Redux and Pondamine and current Redux clinical studies. Georgetown University Medical Center, Washington, DC, March 1998;31.
16.
16. Institute of Medicine. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC: National Academy Press, 1995.
17.
17. Silverstone T, Goodall, E. Centrally acting anorectic drugs: a clinical perspective. Am J Clin Nutr1992;55(Suppl):211S.
18.
18. National Task Force on the Prevention and Treatment of Obesity: Long-term pharmacotherapy in the management of obesity. JAMA1996;276:1907.
19.
19. Fluoxetine (Prozac) and other drugs for treatment of obesity. The Med Lett1994;36:107–8.
20.
20. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res1996;4:263–70.
21.
21. Jones SP, Smith IG, Kelly F, et al. Long term weight loss with sibutramine [Abstract O71.]. Int J Obes1995;19(Suppl 2):41.
22.
22. Drent ML, van der Veen EA. First clinical studies with orlistat: a short review. Obes Res1995;3(Suppl 4):623S.
23.
23. Drent ML, Larsson I, William-Olsson T, et al.Orlistat (RO 18–0647), a lipase inhibitor; in the treatment of human obesity: a multiple dose study. Int J Obes1995;19:221–6.
24.
24. Ravussin E, Lillioja S, Knowler W, et al. Reduced rate of energy expenditure as a risk factor for body weight gain. N Engl J Med1988;318:467–72.
25.
25. Leibel RL, Rosenbaum M, Hirsch, J. Changes in energy expenditure resulting from altered body weight. N Engl J Med1995;332:621–8.
26.
26. Shape Up America! and the American Obesity Association. Guidance for Treatment of Adult Obesity. Bethesda, MD: American Obesity Association, 1996.
27.
27. Brownell, K. The LEARN for Weight Control, 7th ed. Dallas, TX: American Health Publishing Co, 1997.
28.
28. Dhurandhar NV, Atkinson, RL. Comparison of serotonin agonists in combination with phentermine for treatment of obesity. FASEB J1996;10:A561.
29.
29. Crandall, G. Managing obesity with drug therapy. IM1997;18:37–64.
